Voyager Therapeutics Inc. Common Stock
Financials
Valuation Metrics
Voyager Therapeutics Inc. Common Stock's Market Cap is $108M. At end of 2025 it was $231M. Ranked #3053 of 3,114 in US market (top 98%), #1415 of 1,469 on NASDAQ (top 96%), #259 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 98%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $108M | US#3,053/3,114 Sec#259/265 |
| Revenue | $34M | US#2,769/3,114 Sec#155/265 |
| Net Income | $-108M | US—/3,114 Sec—/265 |
| Total Assets | $198M | US#2,985/3,114 Sec#244/265 |
| Net Assets | $154M | US#2,735/3,114 Sec#202/265 |
| Employees | 141 | US#2,553/3,114 Sec#152/265 |
| Value | ||
| P/B | 0.70x | US#203/3,114 Sec#11/265 |
| P/S | 3.12x | US#1,828/3,114 Sec#55/265 |
| FCF Yield | -112.90% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -69.78% | US#2,746/3,114 Sec#187/265 |
| ROA | -54.48% | US#3,000/3,114 Sec#223/265 |
| Op. Margin | -340.08% | US#2,769/3,114 Sec#147/265 |
| Revenue Growth | -19.07% | US#2,639/3,114 Sec#150/265 |
| Financial Health | ||
| Debt Ratio | 28.10% | US#309/3,114 Sec#98/265 |
| Total Debt | $33M | US#2,686/3,114 Sec#172/265 |
| FCF | $-121M | US#2,683/3,114 Sec#163/265 |
| Cash | $36M | US#2,706/3,114 Sec#241/265 |
| Current Ratio | 7.51x | US#334/3,114 Sec#103/265 |
| Performance | ||
| 1Y Return | -61.88% | US#2,985/3,114 Sec#247/265 |
| 1M Return | -27.35% | US#3,041/3,114 Sec#257/265 |
| From 52W High | -67.52% | US#2,921/3,114 Sec#235/265 |
| 1Y MDD | -65.60% | US#2,797/3,114 Sec#215/265 |
| Trading | ||
| Volume | 1,183,708 shares | US#1,305/3,114 Sec#113/265 |
| Trading Value | $2M | US#2,845/3,114 Sec#238/265 |
| Per Share | ||
| EPS | $-1.78 | US—/3,114 Sec—/265 |
| BPS | $2.56 | US#2,526/3,114 Sec#166/265 |
Company Info
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.